Therapeutic options for management of endometrial hyperplasia.
نویسندگان
چکیده
Endometrial hyperplasia (EH) comprises a spectrum of changes in the endometrium ranging from a slightly disordered pattern that exaggerates the alterations seen in the late proliferative phase of the menstrual cycle to irregular, hyperchromatic lesions that are similar to endometrioid adenocarcinoma. Generally, EH is caused by continuous exposure of estrogen unopposed by progesterone, polycystic ovary syndrome, tamoxifen, or hormone replacement therapy. Since it can progress, or often occur coincidentally with endometrial carcinoma, EH is of clinical importance, and the reversion of hyperplasia to normal endometrium represents the key conservative treatment for prevention of the development of adenocarcinoma. Presently, cyclic progestin or hysterectomy constitutes the major treatment option for EH without or with atypia, respectively. However, clinical trials of hormonal therapies and definitive standard treatments remain to be established for the management of EH. Moreover, therapeutic options for EH patients who wish to preserve fertility are challenging and require nonsurgical management. Therefore, future studies should focus on evaluation of new treatment strategies and novel compounds that could simultaneously target pathways involved in the pathogenesis of estradiol-induced EH. Novel therapeutic agents precisely targeting the inhibition of estrogen receptor, growth factor receptors, and signal transduction pathways are likely to constitute an optimal approach for treatment of EH.
منابع مشابه
فراوانی هیپرپلازی آندومتر و عوامل خطرساز آن در بیماران سنین 40-60 سالگی مراجعه کننده به بیمارستان شهید یحیی نژاد بابل در فاصله سالهای 82-1379
Background and Aim: Endometrial hyperplasia is the overgrowth of endometrial glands due to prolonged unopposed estrogenic stimulation. Its major clinical symptom is abnormal uterine bleeding (especially perimenopausal). The disease has several risk factors. The aim of this study was to assess the prevalence of endometrial hyperplasia and its risk factors in perimenopausal period in women who re...
متن کاملP-209: Evaluation of Common Risk Factors in Patients with Endometrial Hyperplasia
Background: One of the most common abnormality in female genital system, especially in premenopausal period, is abnormal uterine bleeding caused by endometrial hyperplasia. Prevalence of endometrial hyperplasia is 5-20% with different risk factors such as hypertension, diabetes mellitus (DM), multiparity, nuliparity, advanced age, and using estrogen consumption. This study try to determine risk...
متن کاملP-99: Relationships between Serum Luteinizing Hormone Level, Endometrial Thickness and Body Mass Index in Polycystic Ovary Syndrome Patients with and without Endometrial Hyperplasia.
Background It is well documented that ulterasonographic endometrial hyperplasia in polycystic ovary syndrome (PCOS) women is strongly related to pathologic endometrial thickness, but there is no consensus on the relation between serum luteinizing hormone (LH) and either of these factors: pathologic endometrial hyperplasia and body mass index (BMI).��� MaterialsAndMethods An observational cross-...
متن کاملبررسی ایمونوهیستوشیمی بروز گیرنده‌های استروژن و پروژسترون در انواع هیپرپلازی و کارسینوم آندومتریویید آندومتر
Background: Endometrial carcinoma (EC) is the most common gynecologic malignancy however, mechanisms underlying its pathogenesis remain obscure. Endometrial carcinoma has been classified into two major categories: type I (related to estrogen or endometrioid adenocarcinoma) and type II (unrelated to estrogen). Estrogen is the main trigger for the abnormal proliferation in the endometrial epithel...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of gynecologic oncology
دوره 27 1 شماره
صفحات -
تاریخ انتشار 2016